Detalles de la búsqueda
1.
Intratumoral delivery of a highly active form of XCL1 enhances antitumor CTL responses through recruitment of CXCL9-expressing conventional type-1 dendritic cells.
Int J Cancer
; 154(12): 2176-2188, 2024 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38346928
2.
Transcutaneous immunization with a highly active form of XCL1 as a vaccine adjuvant using a hydrophilic gel patch elicits long-term CD8+ T cell responses.
J Pharmacol Sci
; 143(3): 182-187, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32386904
3.
Recent Progress in Dendritic Cell-Based Cancer Immunotherapy.
Cancers (Basel)
; 13(10)2021 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-34065346
4.
A Highly Active Form of XCL1/Lymphotactin Functions as an Effective Adjuvant to Recruit Cross-Presenting Dendritic Cells for Induction of Effector and Memory CD8+ T Cells.
Front Immunol
; 9: 2775, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30542351
Resultados
1 -
4
de 4
1
Próxima >
>>